Comparison of EGFR mutation status detected by different methods in tumour tissue and MPE cell block samples
| A. ARMS versus Sanger sequencing for tumour tissue samples | |||
|---|---|---|---|
| ARMS | |||
| Sanger sequencing | + | − | Total |
| + | 27 | 0 | 27 |
| − | 6 | 36 | 42 |
| Total | 33 | 36 | 69 |
| NPV: 36/42 (85.7%); PPV: 27/27 (100.0%). | |||
| B. ARMS versus Sanger sequencing for MPE cell block samples | |||
| ARMS | |||
| Sanger sequencing | + | − | Total |
| + | 4 | 0 | 4 |
| − | 6 | 12 | 18 |
| Total | 10 | 12 | 22 |
| NPV: 12/18 (66.7%); PPV: 4/4 (100.0%). | |||
| C. ARMS versus mutant-specific IHC for tumour tissue samples | |||
| ARMS | |||
| IHC | + | − | Total |
| + | 17 | 1 | 18 |
| − | 14 | 34 | 48 |
| Total | 31 | 35 | 66 |
| NPV: 34/48 (70.8%); PPV: 17/18 (94.4%). | |||
| D. ARMS versus mutant-specific IHC for MPE cell block samples | |||
| ARMS | |||
| IHC | + | − | Total |
| + | 6 | 0 | 6 |
| − | 6 | 14 | 20 |
| Total | 12 | 14 | 26 |
| NPV: 14/20 (75.0%); PPV: 6/6 (100.0%). | |||
ARMS, amplification refractory mutation system; EGFR, epidermal growth factor receptor; IHC, immunohistochemistry; MPE, malignant pleural effusion; NPV, negative predictive value; PPV, positive predictive value.